|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
|
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Gross profit | ||||
| Consulting and marketing | ||||
| Research and Development | ||||
| Depreciation and Amortization | ||||
| General and administrative expenses | ||||
| Settlement agreement expenses | ||||
| Share-based compensation | ||||
| Impairments | ||||
| Professional fees | ||||
| Total operating expense | ||||
| Loss before other income (expense) | ||||
| Finance income | ||||
| Finance expenses | ||||
| Foreign exchange gain (loss) | ||||
| Gain from warrants revaluation | ||||
| Gain (loss) from warrants revaluation | ||||
| Gain (loss) from settlement agreement revaluation | ||||
| Other income (expense) | ||||
| Income (loss) before tax | ||||
| Tax expense | ||||
| Income (loss) for the year | ||||
| Other comprehensive income (loss) | ||||
| Exchange differences on translation | ||||
| Remeasurement of a defined benefit plan, net | ||||
| Other comprehensive income (loss) for the year | ||||
| Total comprehensive income (loss) | ||||
| Income (loss) per share - basic | ||||
| Weighted average number of shares outstanding - basic | ||||
| Income (loss) per share - diluted | ||||
| Weighted average number of shares outstanding - diluted | ||||
Loading...
